Assessment of Ki-67 as a potential biomarker in patients with breast cancer

[1]  Z. Hall.  Cancer , 1906, The Hospital.

[2]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[3]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[6]  F. Spyratos,et al.  Correlation between MIB‐1 and other proliferation markers , 2002, Cancer.

[7]  R. Gelber,et al.  Ki‐67 expression in breast carcinoma , 2003, Cancer.

[8]  L. Goldstein,et al.  Prognostic and predictive factors in early-stage breast cancer. , 2004, The oncologist.

[9]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[11]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[12]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[14]  Mitsuhiro Hayashi,et al.  Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. , 2010, Experimental and therapeutic medicine.

[15]  Sinan Zhu,et al.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance , 2010, Clinical Medicine Insights. Oncology.

[16]  M. Beckmann,et al.  Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) , 2011, Breast Care.

[17]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[18]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[19]  N. Harbeck,et al.  St. Gallen 2011: Summary of the Consensus Discussion , 2011, Breast Care.

[20]  O. Nanni,et al.  Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact , 2012, Oncology.

[21]  K. Kontzoglou,et al.  Correlation between Ki67 and Breast Cancer Prognosis , 2013, Oncology.

[22]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[23]  Stefan Glück,et al.  Molecular Profiling for Breast Cancer: A Comprehensive Review , 2013, Biomarkers in cancer.

[24]  A. Hashmi,et al.  Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[25]  A. Goldhirsch,et al.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. , 2014, Breast.

[26]  M. Herranz,et al.  Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program. , 2014, Anticancer research.

[27]  C. Markopoulos,et al.  The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes , 2014, Anti-cancer drugs.

[28]  San-Gang Wu,et al.  Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study , 2014, PloS one.

[29]  M. Nakano,et al.  Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. , 2014, Molecular and clinical oncology.

[30]  S. Barni,et al.  Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients , 2015, Breast Cancer Research and Treatment.

[31]  John M S Bartlett,et al.  An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.

[32]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.